Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNXNASDAQ:AVXLNASDAQ:DAWNNASDAQ:GYRE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$2.73-5.5%$2.22$1.29▼$7.85$317.08M1.31.46 million shs1.27 million shsAVXLAnavex Life Sciences$9.99-7.4%$8.61$4.24▼$14.44$921.16M0.721.19 million shs1.61 million shsDAWNDay One Biopharmaceuticals$6.63-2.5%$6.68$6.08▼$16.76$689.27M-1.271.15 million shs1.14 million shsGYREGyre Therapeutics$7.62-6.3%$8.92$6.11▼$19.00$762.25M1.72129,008 shs109,710 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon-7.61%+13.75%+5.00%+77.27%-39.20%AVXLAnavex Life Sciences-6.81%+8.35%+20.80%+31.45%+138.42%DAWNDay One Biopharmaceuticals-2.50%+2.00%-7.79%-1.19%-51.64%GYREGyre Therapeutics-6.39%+3.67%-9.39%+5.25%-38.70%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANNXAnnexon2.6545 of 5 stars3.51.00.00.03.12.50.6AVXLAnavex Life Sciences3.5609 of 5 stars3.70.00.04.71.40.80.6DAWNDay One Biopharmaceuticals1.6934 of 5 stars3.62.00.00.00.02.50.0GYREGyre Therapeutics0.082 of 5 stars0.02.00.00.00.60.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 3.00Buy$12.50357.88% UpsideAVXLAnavex Life Sciences 3.33Buy$44.00340.44% UpsideDAWNDay One Biopharmaceuticals 3.14Buy$29.00337.41% UpsideGYREGyre Therapeutics 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownLatest ANNX, GYRE, DAWN, and AVXL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025ANNXAnnexonHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $14.005/13/2025ANNXAnnexonNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $11.005/7/2025DAWNDay One BiopharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$25.005/7/2025DAWNDay One BiopharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $27.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$2.75 per shareN/AAVXLAnavex Life SciencesN/AN/AN/AN/A$1.42 per shareN/ADAWNDay One Biopharmaceuticals$131.16M5.12N/AN/A$4.99 per share1.33GYREGyre Therapeutics$105.76M6.76$0.19 per share41.17$1.05 per share7.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$138.20M-$1.18N/AN/AN/AN/A-54.45%-46.56%8/11/2025 (Estimated)AVXLAnavex Life Sciences-$43M-$0.55N/AN/AN/AN/A-40.93%-36.38%8/5/2025 (Estimated)DAWNDay One Biopharmaceuticals-$95.50M-$0.71N/AN/AN/A-42.66%-14.98%-13.04%7/8/2025 (Estimated)GYREGyre Therapeutics$12.09M$0.02381.19∞N/A7.20%9.73%7.66%8/12/2025 (Estimated)Latest ANNX, GYRE, DAWN, and AVXL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q3 2025AVXLAnavex Life Sciences-$0.13N/AN/AN/AN/AN/A7/29/2025Q2 2025DAWNDay One Biopharmaceuticals-$0.35N/AN/AN/A$35.55 millionN/A5/13/2025Q2 2025AVXLAnavex Life Sciences-$0.16-$0.13+$0.03-$0.13N/AN/A5/12/2025Q1 2025ANNXAnnexon-$0.30-$0.37-$0.07-$0.37N/AN/A5/9/2025Q1 2025GYREGyre Therapeutics$0.03$0.03N/AN/A$28.40 million$22.06 million5/6/2025Q1 2025DAWNDay One Biopharmaceuticals-$0.46-$0.35+$0.11-$0.35$30.28 million$30.76 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/AAVXLAnavex Life SciencesN/AN/AN/AN/AN/ADAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/AGYREGyre TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A7.997.99AVXLAnavex Life SciencesN/A6.746.74DAWNDay One BiopharmaceuticalsN/A10.6210.55GYREGyre TherapeuticsN/A3.603.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/AAVXLAnavex Life Sciences31.55%DAWNDay One Biopharmaceuticals87.95%GYREGyre Therapeutics23.99%Insider OwnershipCompanyInsider OwnershipANNXAnnexon12.67%AVXLAnavex Life Sciences11.00%DAWNDay One Biopharmaceuticals6.20%GYREGyre Therapeutics10.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60109.71 million95.81 millionOptionableAVXLAnavex Life Sciences4085.37 million75.98 millionOptionableDAWNDay One Biopharmaceuticals60101.36 million95.08 millionOptionableGYREGyre Therapeutics4093.76 million84.38 millionNo DataANNX, GYRE, DAWN, and AVXL HeadlinesRecent News About These CompaniesGyre Therapeutics: Unique Business Model, Unique ChallengesJune 30, 2025 | seekingalpha.comGYRE - Gyre Therapeutics Inc Sustainability - MorningstarJune 26, 2025 | morningstar.comMGyre Therapeutics, Inc. (GYRE) Latest Press Releases & Corporate News - Yahoo FinanceJune 24, 2025 | ca.finance.yahoo.comPublic companies account for 71% of Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ownership, while individual investors account for 19%June 20, 2025 | finance.yahoo.comGyre Therapeutics (NASDAQ:GYRE) Trading Up 4% - Here's What HappenedJune 17, 2025 | marketbeat.comGyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest UpdateJune 15, 2025 | marketbeat.comPhase 1 trial of F230 oral therapy for PAH doses 1st participantJune 13, 2025 | pulmonaryhypertensionnews.comPGyre Therapeutics (NASDAQ:GYRE) Stock Price Down 6% - What's Next?June 11, 2025 | marketbeat.comGNI Group’s Gyre Therapeutics Begins Phase 1 Trial for PAH Drug in ChinaJune 11, 2025 | msn.comGyre Therapeutics Inc.: Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in ChinaJune 10, 2025 | finanznachrichten.deGyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in ChinaJune 10, 2025 | globenewswire.comGyre Therapeutics, Inc. (GYRE) Raises $23M in Public Stock Offering to Fund Liver Fibrosis TrialsMay 31, 2025 | finance.yahoo.comGyre Therapeutics, Inc. (GYRE) Raises $23M in Public Stock Offering to Fund Liver Fibrosis TrialsMay 30, 2025 | msn.comGyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesMay 29, 2025 | finance.yahoo.comGyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesMay 29, 2025 | globenewswire.comGyre Therapeutics launches public stock offeringMay 24, 2025 | investing.comGyre Therapeutics announces new stock offeringMay 24, 2025 | uk.investing.comGyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB ...May 24, 2025 | morningstar.comMGyre Therapeutics Announces Positive Phase 3 Trial Results for Hydronidone in Liver Fibrosis Treatment, Paving Way for NDA Submission in 2025May 24, 2025 | nasdaq.comGyre Therapeutics Announces Commencement of Underwritten Public Offering of Common StockMay 24, 2025 | nasdaq.comGyre Therapeutics Shares Fall as Stock Offering Overshadows Positive Trial DataMay 23, 2025 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANNX, GYRE, DAWN, and AVXL Company DescriptionsAnnexon NASDAQ:ANNX$2.73 -0.16 (-5.54%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$2.76 +0.03 (+1.25%) As of 07/7/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Anavex Life Sciences NASDAQ:AVXL$9.99 -0.80 (-7.41%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$10.04 +0.05 (+0.55%) As of 07/7/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Day One Biopharmaceuticals NASDAQ:DAWN$6.63 -0.17 (-2.50%) As of 07/7/2025 04:00 PM EasternDay One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Gyre Therapeutics NASDAQ:GYRE$7.62 -0.51 (-6.27%) As of 07/7/2025 04:00 PM EasternGyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
